Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
Antibodies, Bispecific
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Child, Preschool
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation
Histone-Lysine N-Methyltransferase
/ analysis
Humans
Infant
Kaplan-Meier Estimate
Male
Myeloid-Lymphoid Leukemia Protein
/ analysis
Neoplasm, Residual
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Recurrence
Salvage Therapy
acute lymphoblastic leukaemia
blinatumomab
haematopoietic stem cell transplantation
infants
minimal residual disease
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
11
02
2021
accepted:
16
03
2021
pubmed:
13
4
2021
medline:
17
12
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
Blinatumomab with subsequent haematopoietic stem cell transplantation was applied in 13 infants with acute lymphoblastic leukaemia (ALL). Eight patients were treated in first remission due to slow clearance of minimal residual disease (MRD); one for MRD-reappearance after long MRD negativity, one for primary refractory disease and three during relapse treatment. In slow MRD responders, complete MRD response was achieved prior to transplantation, with an 18-month event-free survival of 75%. In contrast, only one of five patients with relapsed/refractory ALL is still in complete remission. These data provide a basis for future studies of immunotherapy in very high-risk infant ALL.
Substances chimiques
Antibodies, Bispecific
0
Antineoplastic Agents, Immunological
0
KMT2A protein, human
0
Myeloid-Lymphoid Leukemia Protein
149025-06-9
blinatumomab
4FR53SIF3A
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-178Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Tomizawa D. Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatr Int. 2015;57:811-9.
Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol. 2019;37:2246-56.
Brown PA. Neonatal leukemia. Clin Perinatol. 2021;48(1):15-33.
Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-17.
Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 protocol. J Clin Oncol. 2021;39:652-62.
Tsaur G, Popov A, Riger T, Kustanovich A, Solodovnikov A, Shorikov E, et al. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. Br J Haematol. 2021 [Online ahead of print]. https://doi.org/10.1111/bjh.17304
Popov A, Buldini B, De Lorenzo P, Disaro S, Verzhbitskaya T, Movchan L, et al. Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia. 2020;34:3042-6.
Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30:1184-7.
Sison EA, Brown P. Does hematopoietic stem cell transplantation benefit infants with acute leukemia? Hematology. 2013;2013:601-4.
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381-9.
Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019;3:1926-9.
Mikhailova E, Gluhanyuk E, Illarionova O, Zerkalenkova E, Kashpor S, Miakova N, et al. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab. Haematologica. 2020 [Online ahead of print]. https://doi.org/10.3324/haematol.2019.241596.
Fuster JL, Molinos-Quintana A, Fuentes C, Fernandez JM, Velasco P, Pascual T, et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br J Haematol. 2020;190:764-71.
Clesham K, Rao V, Bartram J, Ancliff P, Ghorashian S, O'Connor D, et al. Blinatumomab for infant acute lymphoblastic leukemia. Blood. 2020;135:1501-4.
Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406-10.
Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3:3393-405.